CD8A and primary cutaneous T-cell non-Hodgkin lymphoma: In contrast, allogeneic CD8 or pan CAR-Vβ2 T cells generated from healthy donors were highly efficient in on-target killing of Vβ2+ malignant T cells directly isolated from CTCL/PTCL patients, with demonstrated specificity and safety when endogenous TCRs are knocked out to minimize potential GVH activity.